No Data
No Data
Spero Therapeutics (SPRO) Was Downgraded to a Hold Rating at Evercore ISI
Evercore ISI Group Downgrades Spero Therapeutics to In-Line, Maintains Price Target to $5
Spero Therapeutics Downgraded at Evercore on Lack of Capital Allocation Clarity
Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study